Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs
Michela Giuliano1, Antonella D'Anneo, Anna De Blasio
1Dipartimento di Biologia Cellulare e dello Sviluppo, Sezione di Biochimica, Policlinico, Università di Palermo, Italy.
Abstract:
This report reviews the current status of extensive efforts directed towards the interpretation of crosstalk between apoptosis and proteasome to understanding the molecular mechanism of anticancer agents targeting proteasome, with particular focus on MG132 and PS-341. The discovery that all cancer cells have retained the apoptotic death program has offered to the researchers new biochemical targets to design anticancer drugs. Moreover, the demonstration that proteasome inhibition induces apoptosis and sensitizes cancer cells to traditional tumoricidal agents has proposed the proteasome as an attractive target for development of new anticancer drugs. Since then, a number of both naturally occurring and synthetic inhibitors of the proteasome have been identified. The best characterized and most widely used inhibitors of the proteasome are the peptide aldehydes; among these MG132, due to its broad spectrum of action, low cost and rapid reversibility of action, still remains the first choice to study proteasome function in cell and tissue cultures. Recently, a very potent new class of selective and reversible proteasome inhibitors which contains an inhibitory boronate group has been described. PS-341 represent the first of this promising class of agents that could have application in cancer therapy and it is the only that has progressed to clinical trials.
Insights
Understanding the interplay between apoptosis and proteasome function is key to developing novel anticancer agents. Proteasome inhibition, using drugs like MG132 and PS-341, effectively induces cancer cell death.
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Cancer cells retain the apoptotic death program, offering new therapeutic targets.
- Proteasome inhibition is a promising strategy for cancer drug development.
- The crosstalk between apoptosis and proteasome is crucial for understanding cancer cell death.
Purpose of the Study:
- To review the current understanding of apoptosis and proteasome crosstalk.
- To examine the molecular mechanisms of proteasome-targeting anticancer agents.
- To focus on the roles of MG132 and PS-341 in cancer therapy.
Main Methods:
- Review of existing scientific literature on proteasome inhibitors and apoptosis.
- Analysis of the molecular mechanisms of action for MG132 and PS-341.
- Discussion of preclinical and clinical findings related to proteasome inhibitors.
Main Results:
- Proteasome inhibition effectively induces apoptosis in cancer cells.
- MG132 is a widely used, cost-effective inhibitor for studying proteasome function.
- PS-341 represents a novel class of selective proteasome inhibitors with therapeutic potential.
Conclusions:
- Targeting the proteasome offers a viable strategy for anticancer drug design.
- Further research into proteasome inhibitors like PS-341 is warranted for cancer treatment.
- Understanding the apoptosis-proteasome axis is critical for advancing cancer therapy.
Related Concept Videos
01:30Apoptosis
01:31The Intrinsic Apoptotic Pathway
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:18Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
01:17The Extrinsic Apoptotic Pathway